- Research article
- Open Access
- Open Peer Review
Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-β
BMC Cancer volume 7, Article number: 52 (2007)
XIAP-associated factor 1 (XAF1) is a putative tumor suppressor that exerts its proapoptotic effects through both caspase-dependent and – independent means. Loss of XAF1 expression through promoter methylation has been implicated in the process of tumorigenesis in a variety of cancers. In this report, we investigated the role of basal xaf1 promoter methylation in xaf1 expression and assessed the responsiveness of cancer cell lines to XAF1 induction by IFN-β.
We used the conventional bisulfite DNA modification and sequencing method to determine the methylation status in the CpG sites of xaf1 promoter in glioblastoma (SF539, SF295), neuroblastoma (SK-N-AS) and cervical carcinoma (HeLa) cells. We analysed the status and incidence of basal xaf1 promoter methylation in xaf1 expression in non-treated cells as well as under a short or long exposure to IFN-β. Stable XAF1 glioblastoma knock-down cell lines were established to characterize the direct implication of XAF1 in IFN-β-mediated sensitization to TRAIL-induced cell death.
We found a strong variability in xaf1 promoter methylation profile and responsiveness to IFN-β across the four cancer cell lines studied. At the basal level, aberrant promoter methylation was linked to xaf1 gene silencing. After a short exposure, the IFN-β-mediated reactivation of xaf1 gene expression was related to the degree of basal promoter methylation. However, in spite of continued promoter hypermethylation, we find that IFN-β induced a transient xaf1 expression, that in turn, was followed by promoter demethylation upon a prolonged exposure. Importantly, we demonstrated for the first time that IFN-β-mediated reactivation of endogenous XAF1 plays a critical role in TRAIL-induced cell death since XAF1 knock-down cell lines completely lost their IFN-β-mediated TRAIL sensitivity.
Together, these results suggest that promoter demethylation is not the sole factor determining xaf1 gene induction under IFN-β treatment. Furthermore, our study provides evidence that XAF1 is a crucial interferon-stimulated gene (ISG) mediator of IFN-induced sensitization to TRAIL in cancer.
Cell life and death decisions rely on a delicate balance between pro- and anti-apoptotic factors. A disruption of this balance can result in a variety of pathologies including cancer, autoimmune and neurodegenerative diseases. In cancer cells, anti-apoptotic factors such as the Inhibitors of Apoptosis (IAPs) render cells resistant to apoptosis, primarily through their inhibition of core death executioners, the caspases, or through the neutralization of antagonists such as Smac/DIABLO and Omi/HtrA2 . In particular, Baculovirus IAP Repeat domains (BIRs) present in XIAP can interact directly and inhibit initiator and/or effector caspases. In addition, the RING finger domain present in some IAPs such as XIAP and cIAP-1 acts as an E3 ubiquitin ligase, targeting the IAP-caspase complex for degradation via the proteasome . Thus, IAP function is central to the modulation of the apoptotic cascade.
To counter the effects of the IAPs, several antagonists such as XIAP-Associated Factor-1 (XAF1), Smac/DIABLO and Omi/HtrA2 have been identified that play essential roles in apoptosis . XAF1 has been independently identified in several screens as a key mediator of apoptosis [4–6] and is shown to dramatically sensitize cancer cells to apoptotic triggers such as TNF-related apoptosis-inducing ligand (TRAIL) and etoposide treatments [4, 7]. This sensitization is in part achieved through XAF1 inhibition of XIAP anti-caspase activity. In addition, XAF1 also appears to enhance the apoptotic effects of TNF-α independently of its interaction with XIAP . Furthermore, in urogenital cancers, XAF1 was recently shown to quicken the apoptosis response through its enhancement of p53 protein stability . These recent findings identify XAF1 as a candidate tumor suppressor at the junction of several major pathways leading to apoptosis.
The loss of XAF1 is associated with malignant tumor progression in a variety of cancers. XAF1 levels are drastically decreased in a significant number of cancer cell lines [5, 9], as well as in a collection of gastric cancers , melanoma specimens  and urogenital cancers . Loss of XAF1 is due, at least in part, to epigenetic alterations such as DNA methylation at several CpG sites within the promoter region [6, 10]. In gastric cancers, the relative decrease in xaf1 transcript level correlates with the stage and grade of the tumor, suggesting that loss of XAF1 contributes to the process of tumorigenesis . It is therefore predicted that methods that enhance XAF1 levels could increase apoptotic susceptibility and provide an additional strategy for cancer therapy.
In this context, the discovery of xaf1 as an Interferon Stimulated Gene (ISG) provides evidence for the feasibility of such a therapeutic strategy. The induction of XAF1 by IFN-β in human melanoma cell lines results in enhanced susceptibility to TRAIL-induced apoptosis . Expression of a truncated XAF1 protein lacking part of a zinc-finger domain abrogates IFN-dependent sensitization to TRAIL, suggesting that XAF1 plays an essential role in IFN-mediated apoptosis. A potential pitfall of the use of IFN to induce xaf1 expression is the frequent hypermethylation of the xaf1 promoter observed in many cancer cell lines [6, 10]. Promoter hypermethylation can lead to transcriptional gene silencing through the assembly of condensed chromatin domains or through simple inhibition of transcription factor binding . DNA methylation and the subsequent silencing of several IFN pathway components including RNAseL and RNA-activated protein kinase (PKR) has been identified as a major mechanism associated with carcinogenesis [12, 13]. The reversal of the DNA methylation status, through treatment with the methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-AZA-dC) can restore cell susceptibility to IFN [13, 14]. Although in the large majority of cases there is a strong correlation between promoter methylation and resistance to induction by IFN, exceptions exist. In neuroblastoma cells, treatment with IFN-γ can induce methylation-silenced caspase-8 expression without affecting the methylation status within the promoter region . As a plausible explanation, an alternative IFN-inducible promoter element has been found upstream of the first exon of caspase-8 gene and has been shown to be responsive to IFN-γ, independently of the methylation status [15, 16].
In this report, we investigate the effect of IFN-β on the methylation status of xaf1 promoter and on the expression of xaf1 in SF539 and SF295 glioblastoma, SK-N-AS neuroblastoma and HeLa cervical carcinoma. In cancer cells, we find a strong correlation between methylation status of the xaf1 promoter and baseline gene expression at the transcript level. HeLa and SK-N-AS cell lines show the highest basal promoter hypermethylation among the four cancer cell lines studied compared to control cells, and are used as cellular models for studying the responsiveness of IFN-β-mediated XAF1 induction. In spite of basal promoter hypermethylation, IFN-β could induce xaf1 expression in HeLa and SK-N-AS. Futhermore, we demonstrate that IFN-β induced a transient increase in the xaf1 transcript and protein levels apparent at 48 hours post-treatment. However, we do not find a tight link between IFN-β-mediated xaf1 gene induction and decrease in average methylation within xaf1 promoter region in HeLa and SK-N-AS cells occurring at later time points. These results suggest that xaf1 expression would be positively regulated by additional mechanisms other than promoter demethylation. To further understand the importance of xaf1 gene induction in IFN-β-sensitization to TRAIL-mediated cell death, we established stable glioblastoma SF539 cell lines carrying specific xaf1 shRNA. We find that xaf1 knockout stable SF539 clones are unresponsive to IFN-β-mediated XAF1 induction, rendering these stable cell lines resistant to sensitization by IFN-β to TRAIL-mediated cell death. Our study clearly demonstrates that xaf1 is a critical ISG implicated in IFN-β-mediated sensitization to TRAIL-induced cell death.
Cell culture and transfection
Glioblastoma (SF539 and SF295) and neuroblastoma (SK-N-AS) cell lines were maintained on Dulbecco's Modified Eagle Medium (DMEM), 10% foetal bovine serum (FBS), supplemented with 4 mM glutamine and 0.1 mM non-essential amino-acids. Cervical carcinoma (HeLa) cells were maintained in Minimal Essential Medium (MEM), 10% FBS supplemented with 2 mM glutamine and 0.1 mM non-essential amino acids. For transfection, cells were grown to 70%–80% confluency in 6-well plates and transfected with linearized plasmid DNA using Lipofectamine 2000 (Invitrogen, Burlington ON, Canada) according to the manufacturer's recommendations. Stable clones were selected in DMEM supplemented with 600 μg/mL G418 (Invitrogen).
When required, IFN-β (R&D Systems, Minneapolis, MN, USA) was added at a concentration of 500 U/mL and 5-aza-2'-deoxycytidine (Sigma-Aldrich) at the doses indicated.
Xaf1 short hairpin RNA (shRNA) plasmid construction and screening
The design and construction of the shRNA clones against xaf1 was performed according to the shagging-PCR method described previously . PCR amplification reactions were performed on U6 promoter template using a forward primer (5'-AGGAGATCTGCGCAGGCAAAACGCACCAC-3') and a variety of 96 nucleotide-long shRNA xaf1 primers based on a similar approach described previously for shRNA XIAP . PCR products were cloned into a TOPO-TA vector (Invitrogen) and were screened for activity by transient transfection into 293T cells followed by xaf1 transcript quantification by quantitative RT-PCR. One of the constructs that caused a significant decrease in xaf1 transcript levels was selected for stable transfection into glioblastoma SF539 cells. The construct targets exon-2 that is shared among the three major splice isoforms of xaf1 (5'-CCATGGAGGAGCACTGCAAGCTTGAGCAC-3'). The shRNA was sub-cloned into a pCDNA3 vector devoid of its CMV promoter  and transfected into SF539 cells as described above.
Quantitative RT-PCR using xaf1-specific primers and the TaqMan method  was performed as described previously . Briefly, total RNA was extracted from 1 × 107 cells using the RNeasy kit (Qiagen, Mississauga ON, Canada). 100 ng aliquots were assayed by reverse-transcription followed by PCR (TaqMan EZ-RT PCR kit, Applied Biosystems, Foster City CA, USA) with xaf1-specific primer/probe combinations . GAPDH primer and probes were used as a control. All assays were performed at least in triplicate.
Western blot analysis
Cells were grown in 6-well plates at a density of ~7 × 105 cells per well. Cells were either treated or not with IFN-β (500 U/mL) for 24 hours or more, harvested by scraping, washed twice in PBS (pH 7.2) and lysed with boiling lysis buffer (1% SDS, 1 mM ortho-vanadate, 10 mM tris pH 7.4). Protein concentration was determined with the RC DC Bradford assay (BioRad, Montreal QC, Canada). 20 μg to 30 μg of total protein in SDS sample buffer was resolved by SDS-PAGE (10% or 12.5%) and transferred to PVDF membrane using a semi-dry transfer system (Hoepher SemiPhor). Membranes were blocked overnight in PBS (0.1% Tween, 5% skim milk) and were incubated with primary antibody (PBS, 2% skim milk) for 12 to 16 hours at 4°C. The membrane was incubated with secondary antibody (PBS, 2% skim milk) for two hours and the signal was revealed by enhanced chemiluminescence (ECL) or ECL-Plus kits (Amersham Biosciences, Baie d'Urfe, QC, Canada). Mouse monoclonal anti-XAF1 and rabbit polyclonal anti-XIAP antibodies were generated against their respective full-length GST-tagged construct following standard techniques. Antibodies against β-actin and GAPDH were obtained from Sigma and Advanced Immunochemical, respectively.
Bisulphite DNA sequencing
Cells were grown to 80% confluency in 10 cm plates and harvested by scraping. Genomic DNA was extracted using the DNeasy kit (Qiagen). Approximately 1 μg of DNA was modified with sodium bisulphite as outlined previously . Modified DNA was used as a template in PCR reactions with primers MS2 and MS3 . PCR products were cloned into TOPO-TA vector and transformed into E. coli XL-10 gold cells (Stratagene) and 10 positive clones were randomly selected for sequencing. Methylation status was assessed at eight CpG sites situated within a 250 bp region upstream of the translational start site, whose methylation status was previously shown to correlate with xaf1 gene silencing . As a control, DNA was extracted from buffy coat preparations of blood samples donated by two healthy volunteers. Control DNA was processed as described above.
Cell viability assay
Cells were seeded in 96 well plates at 1 × 105 cells per well (100 μl of medium) and were allowed to adhere for at least 8 hours. Growth medium was replaced with medium containing TRAIL at concentrations ranging from 0 to 100 ng/mL and cell viability was assessed 16 to 20 hours later by the WST-1 assay (Roche Diagnostics, Laval QC Canada).
Relationship between basal profile of xaf1 promoter methylation and IFN-β-mediated induction of xaf1expression
Four cancer cell lines, SF295, SF539, SK-N-AS and HeLa were selected to investigate the effect of xaf1 promoter methylation on IFN-β mediated xaf1 induction. Of these, glioblastoma SF295 cells have previously been shown to carry little or no detectable XAF1 protein . In contrast, the SF539 cell line expresses substantial amounts of XAF1 protein, compared to other cancer cell lines examined . In order to assess the degree of xaf1 promoter methylation within these cell lines, a bisulphite DNA modification and sequencing was performed. The methylation status of 8 CpG sites situated within a 250 bp region immediately upstream of the translational start and corresponding to part of the xaf1 promoter was PCR amplified and 10 PCR clones were isolated and sequenced (Figure 1A and 1B). The methylation status was compared to control total blood DNA obtained from healthy volunteers. Cancer cell lines tested vary extensively in their degree of methylation (Figure 1B). HeLa (average methylation at all sites 37.5%) and SK-N-AS (77.5%) cells display significantly more methylated CpG sites than control samples (9.3%), SF295 (0%) and SF539 (1.3%) (Figure 1C). The degree of promoter methylation is inversely correlated with xaf1 transcript levels measured by quantitative RT-PCR (Figure 1D). Cell lines SF539 and SF295 that display low promoter methylation have comparatively more xaf1 transcript than HeLa and SK-N-AS cell lines.
To assess the effect of IFN-β on xaf1 gene expression in the context of basal xaf1 promoter methylation, cells were treated with 500 U/mL IFN-β for 24 hours and xaf1 transcript levels were measured by quantitative RT-PCR (Figure 1D). A strong inverse correlation exists between basal xaf1 promoter methylation and transcription induction by IFN-β. Cell lines displaying high levels of basal methylation (e.g. SK-N-AS and HeLa) show minimal xaf1 induction, whereas cell lines with no or little methylation display enhanced levels of xaf1 transcript (e.g. SF295 and SF539) in response to IFN-β. IFN-β treatment also causes a significant increase in XAF1 protein level in cell lines displaying low levels of basal promoter methylation (Figure 1E). XAF1 protein induction is not detectable in cell lines with very high levels of promoter methylation (data not shown).
To assess the effect of IFN-β on XAF1 protein expression under demethylating conditions, we have compared the effects of the DNA methylation inhibitor 5-AZA-dC and IFN-β treatment alone and in combination. Treatment with 5-AZA-dC alone up-regulated the expression of XAF1 in HeLa cells (hypermethylated xaf1 promoter at baseline) but had no effect in SF295 (hypomethylated xaf1 promoter at baseline) used as a control. The combination of 5-AZA-dC and IFN-β synergistically induced XAF1 expression in HeLa cells. However, no such effect was detected in cell lines lacking xaf1 promoter methylation (SF295) (Figure 1F). Treatment with IFN-β induced XAF1 expression regardless of the promoter methylation status of the cells suggesting a more complex mechanism of xaf1 transcriptional regulation.
Methylation dynamics of xaf1 promoter in cancer cell lines after prolonged IFN-β treatment
The observation that cell lines heavily methylated within the xaf1 promoter still respond to IFN-β treatment (i.e. 72- and 266-fold xaf1 transcript induction in SK-N-AS and HeLa cells, respectively, Figure 1C) suggested that transcriptional silencing associated with xaf1 promoter methylation may be reversible. To address this possibility, we surveyed xaf1 promoter methylation status in HeLa and SK-N-AS cells exposed of 500 U/mL IFN-β for up to five days, followed by a seven-day recovery in medium without IFN-β. A continuous five day treatment with IFN-β caused a significant demethylation of most previously methylated CpG sites that was confirmed by bisulfite DNA modification and sequencing analysis (Figure 2A). Indeed, IFN-β caused a net 76% and 44% reduction in promoter methylation in HeLa and SK-N-AS cells, respectively (Figures 2A and 2B). After 7 days without IFN-β, the level of methylation remained unchanged, indicating that the demethylated status of xaf1 promoter was stable.
Next, we analyzed the expression levels of xaf1 transcript (Figures 3A and 3B) and protein (Figure 3C) following the 5-day IFN-β treatment and 7-day recovery. Intriguingly, in the presence of IFN-β, there is no discernible correlation between promoter demethylation and transcript increase (Figures 2 and 3). Xaf1 transcript and protein levels are correlated to each other, reaching a peak at 48 hours and declining subsequently in both cell lines. Moreover, after IFN-β removal and despite sustained promoter demethylation, xaf1 transcript and protein levels continue to decrease. Thus, although IFN-β treatment resulted in a sustained loss of DNA methylation within the promoter region of xaf1, this treatment was not sufficient in maintaining increased xaf1 transcript or protein levels in the long term.
Endogenous XAF1 is critical for IFN-β-mediated TRAIL-dependent apoptosis
To place xaf1 in a therapeutic context, we evaluated the role of xaf1 expression in susceptibility to TRAIL-induced apoptosis in glioblastoma cells SF539. A previous study has shown that overexpression of xaf1 promotes TRAIL-induced apoptosis in melanoma cells . Here, glioblastoma cells SF539 that display relatively high levels of xaf1 transcript, XAF1 protein and very low levels of promoter methylation were assessed for their susceptibility to TRAIL-induced apoptosis before and after shRNA-mediated xaf1 silencing. Due to the poor efficiency of transfection (20 to 30%) of the SF539 cells, stable clones (SFX1, SFX3, SFX4) expressing a shRNA construct directed against xaf1 were generated. These clones display a complete downregulation of endogenous XAF1 protein levels and abrogate XAF1 induction even after 24 hours of IFN-β treatment (Figure 4). Interestingly, treatment with IFN-β also causes a significant decrease in XIAP protein levels that appears to be at least in part dependent on the induction of XAF1, since this decrease is less marked in shRNA stable cell lines lacking XAF1.
Three of the stable xaf1 shRNA clones as well as the parental SF539 cell line were subjected to various concentrations of TRAIL with or without prior IFN-β treatment. As expected, IFN-β sensitized SF539 cells to TRAIL-induced cell death throughout the range of concentrations used in this experiment (Figure 5). In contrast, all three stable cell lines display a loss of IFN-β-mediated sensitivity to TRAIL, even though they differ in their TRAIL resistance in the absence of IFN-β. Together, these results demonstrate that the induction of endogenous XAF1 by IFN-β plays a critical role in sensitizing cancer cells to TRAIL-induced cell death.
In this study we have explored the relationship of XAF1 expression to gene silencing, promoter methylation and gene induction by IFN-β. Previous studies had indicated that loss of xaf1 expression, due at least in part to promoter methylation, is associated with increased tumor severity in gastric  and urogenital cancers . In addition, XAF1 was shown to play a key role in the mechanism of IFN-β-associated sensitization to apoptotic cell death induced by TRAIL . More recently, XAF1 was demonstrated to be critical in overcoming resistance to apoptosis induction by IFN-β in renal carcinoma and melanoma cells .
First, we validated the relationship between xaf1 silencing and promoter hypermethylation across four cancer cell lines HeLa, SK-N-AS, SF539 and SF295, that was to date, unexplored in this context. Then, we demonstrated that reverse methylation is not an absolute prerequisite for IFN-β-mediated XAF1 induction, since we showed a transient induction of XAF1 at both transcript and protein levels in spite of aberrant methylation, more particularly in HeLa cells. Finally, our results strengthen the importance of XAF1 expression in IFN-β-mediated sensitization to TRAIL-induced cell death in cancer cells.
Our current analysis of the methylation status of the xaf1 promoter is limited to the examination of 8 CpG sites within the proximal promoter region. These CpG sites have been previously validated to be more tightly associated with xaf1 expression compared with others distal CpG sites investigated . In addition, very recently, 2 of the 8 CpGs at -2nd, -1st positions (with respect of the transcriptional start site) were found to be more important in xaf1 transcriptional regulation . However, further studies combining site-directed mutagenesis with methylation techniques will be necessary to ascertain the relevance of these sites in order to demonstrate if some of them are functionally more important than others.
Our results indicate that mechanisms, in addition to DNA methylation, are responsible for the control of XAF1 expression in cancer cells. Consistent with the pleitropic nature of IFN-β, multiple signalling pathways can be expected to be activated upon IFN-β challenge. For example, a large body of evidence has shown that the interaction of IFN-β with its receptor complex induces the transcription of ISGs through a signalling pathway involving the activation of the Janus kinase (JAK) family that in turn, phosphorylate substrate proteins called STATs (signal transducers and activators of transcription) . In addition, the family of transcription factors known as interferon regulatory factors (IRFs) contribute to the numerous biological functions of IFN-α and IFN-β, which then modulate different sets of genes including IFN-α/β and many ISGs genes [24, 25]. Interestingly, after treatment of human hepatoma cells with a combination of IFN-α and IFN-γ, transcriptional induction of selective ISGs (including xaf1) was found to be dependent upon IRF-1 .
In accordance with previous reports, we find a strong inverse correlation between xaf1 promoter methylation and baseline transcript in four cancer cell lines tested. In spite of the high level of promoter methylation in HeLa and SK-N-AS cell lines, a significant increase in xaf1 transcript and protein levels was detected following IFN-β treatment. Although the responsiveness to IFN-β-mediated XAF1 induction is generaly more effective in cells associated with low basal xaf1 promoter methylation, our results indicate that reverse methylation is not the sole factor modulating XAF1 expression. In this regard, we demonstrate that IFN-β has the ability to overcome the epigenetic modification of hypermethylation. Consistent with this result, IFN was previously found to mediate the induction of caspase-8 in neuroblastomas, without affecting promoter methylation [15, 16]. Nevertheless, prolonged exposure to IFN-β leads to significant and stable demethylation of the xaf1 promoter, but long-term expression of the xaf1 transcript and protein remain unaffected by the treatment. We have attempted to provide explanation as to the mechanisms that governs xaf1 demethylation under IFN-β treatment, with respect to the role of DNMTs known in maintaining genes like xaf1 silenced [21, 27]. We have demonstrated a synergistic effect of treatments combining the inhibitor of DNMTs, 5-AZA-dC, and IFN-β on XAF1 re-expression in cells with hypermethylated xaf1 promoter. This suggests that IFN-β may overcome DNMT activity to a certain extent, a finding that is consistent with a previous study showing that selective depletion of DNMT1 leads to demethylation and subsequent reactivation of xaf1 expression. Moreover, in this context, IFN-β-induced apoptosis was found to be dependent on xaf1 expression . Xaf1 promoter methylation represents an initial mechanism of apoptosis resistance displayed by cancer cells. In this regard, it would be interesting to examine the correlation between DNA methyltransferases expression and xaf1 promoter methylation status in various cancer cell lines to evaluate their response to IFN-β-induced apoptosis.
These findings stress the importance of factors independent from DNA methylation that directly or indirectly control xaf1 expression. Very recently, studies have reported new transcriptional regulatory elements within the proximal 5' region of xaf1 promoter. Interestingly, under specific stress pressure, the heat-shock transcription factor 1 (HSF1) was demonstrated to function as a negative regulator of xaf1 expression in various gastroinstestinal cancer tissues and cell lines . However, the potential influence of DNA methylation on HSF1 binding-mediated suppression of XAF1 transcription has not been studied. Conversely, XAF1 was found to be modulated positively (independently of DNA methylation) by all-trans retinoic acid (ATRA) and IFN through an IFN regulatory factor 1 binding element (IRF-E) that mediates transcription regulation and participates in ATRA-induced induced cell-growth suppression . However a significant contribution of HSF1 or IRF-1 in IFN-β-mediated transient XAF1 expression observed in our study remains to be confirmed. On the other hand, IFN-β induces ISGs of which xaf1 is a member, through a JAK kinase cascade which in turn activates STAT factors [23, 30]. Therefore, modifications in the activity of any of the members of the IFN-β cascade can be potentially responsible for modifications in xaf1 transcription that are independent of xaf1 promoter methylation.
We have demonstrated that endogenous XAF1 expression is crucial for the IFN-β-associated sensitization to TRAIL. The loss of XAF1 in three different shRNA stable glioblastoma cell lines completely abolished the sensitization effect of IFN-β observed in the parental SF539. The lack of XAF1 induction following IFN-β treatment in these stable cell lines demonstrates the efficacy of the shRNAs in suppressing XAF1 expression even in the presence of a proven inducer of the gene. Importantly, these findings allowed us to examine the relationship between endogenous XAF1, IFN-β and TRAIL-mediated apoptosis. Significantly, a previous report has demonstrated the critical role of XAF1 in overcoming resistance to IFN-β-induced apoptosis in the absence of DNMT1 expression, a result that supports our current findings .
Among the multitude of genes that are modulated by IFN [31, 32] and can potentially enhance cell sensitivity to TRAIL-induced apoptosis, we show that xaf1 alone is important and essential in mediating susceptibility to TRAIL-induced apoptosis in cancer cells. Functional knockdown of xaf1 through shRNA is sufficient to eliminate the IFN-β-mediated sensitization to TRAIL in glioblastoma cells. Although TRAIL is a potent apoptotic trigger in many cancer cells, resistance to TRAIL, either intrinsic or acquired, currently represents a substantial limitation to therapy . IFN treatment has been shown to overcome TRAIL resistance , however, resistance to the dual IFN/TRAIL therapy has also been observed . In this context, the centrality of XAF1 in IFN-regulated apoptosis might be the key in reversing TRAIL-resistance.
In conclusion, we demonstrate that, in spite of aberrant hypermethylation of the xaf1 gene, IFN-β was able to induce xaf1 expression. Furthermore, although promoter methylation is a good predictor to basal XAF1 expression, demethylation does not necessarily lead to sustained XAF1 expression. However, it is clear that XAF1 is an important mediator in sensitizing IFN-treated cells to TRAIL-induced killing. These results suggest that the incorporation of xaf1 in combination regimens might be of particular value in TRAIL-based anti-cancer strategies.
Wright CW, Duckett CS: Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest. 2005, 115: 2673-2678. 10.1172/JCI26251.
Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science. 2000, 288: 874-877. 10.1126/science.288.5467.874.
Liston P, Fong WG, Korneluk RG: The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene. 2003, 22: 8568-8580. 10.1038/sj.onc.1207101.
Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, Tamai K, Craig CG, McBurney MW, Korneluk RG: Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol. 2001, 3: 128-133. 10.1038/35055027.
Ng KC, Campos EI, Martinka M, Li G: XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol. 2004, 123: 1127-1134. 10.1111/j.0022-202X.2004.23467.x.
Lee MG, Huh JS, Chung SK, Lee JH, Byun DS, Ryu BK, Kang MJ, Chae KS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG: Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses. Oncogene. 2006, 25: 5807-5822. 10.1038/sj.onc.1209867.
Leaman DW, Chawla-Sarkar M, Vyas K, Reheman M, Tamai K, Toji S, Borden EC: Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem. 2002, 277: 28504-28511. 10.1074/jbc.M204851200.
Xia Y, Novak R, Lewis J, Duckett CS, Phillips AC: Xaf1 can cooperate with TNFalpha in the induction of apoptosis, independently of interaction with XIAP. Mol Cell Biochem. 2006, 286: 67-76. 10.1007/s11010-005-9094-2.
Fong WG, Liston P, Rajcan-Separovic E, St Jean M, Craig C, Korneluk RG: Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics. 2000, 70: 113-122. 10.1006/geno.2000.6364.
Byun DS, Cho K, Ryu BK, Lee MG, Kang MJ, Kim HR, Chi SG: Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res. 2003, 63: 7068-7075.
Karpf AR, Jones DA: Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 2002, 21: 5496-5503. 10.1038/sj.onc.1205602.
Kulaeva OI, Draghici S, Tang L, Kraniak JM, Land SJ, Tainsky MA: Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene. 2003, 22: 4118-4127. 10.1038/sj.onc.1206594.
Chen B, He L, Savell VH, Jenkins JJ, Parham DM: Inhibition of the interferon-gamma/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. Cancer Res. 2000, 60: 3290-3298.
Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U, Stahel R: Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 2003, 10: 356-364. 10.1038/sj.cdd.4401157.
Kim S, Kang J, Evers BM, Chung DH: Interferon-gamma induces caspase-8 in neuroblastomas without affecting methylation of caspase-8 promoter. J Pediatr Surg. 2004, 39: 509-515. 10.1016/j.jpedsurg.2003.12.009.
Casciano I, Banelli B, Croce M, De Ambrosis A, di Vinci A, Gelvi I, Pagnan G, Brignole C, Allemanni G, Ferrini S, Ponzoni M, Romani M: Caspase-8 gene expression in neuroblastoma. Ann N Y Acad Sci. 2004, 1028: 157-167. 10.1196/annals.1322.017.
Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002, 16: 948-958. 10.1101/gad.981002.
McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, Morris SJ, Durkin JP, Lacasse EC: Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene. 2004, 23: 8105-8117. 10.1038/sj.onc.1207967.
Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res. 1996, 6: 986-994.
Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003, 349: 2042-2054. 10.1056/NEJMra023075.
Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, MacLeod AR, Borden EC: Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol. 2006, 24: 3771-3779. 10.1200/JCO.2005.03.4074.
Zou B, Chim CS, Zeng H, Leung SY, Yang Y, Tu SP, Lin MC, Wang J, He H, Jiang SH, Sun YW, Yu LF, Yuen ST, Kung HF, Wong BC: Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology. 2006, 131: 1835-1843. 10.1053/j.gastro.2006.09.050.
Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC: Human interferons alpha, beta and omega. Growth Factors. 2004, 22: 243-251. 10.1080/08977190400000833.
Taniguchi T, Ogasawara K, Takaoka A, Tanaka N: IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001, 19: 623-655. 10.1146/annurev.immunol.19.1.623.
Baccala R, Kono DH, Theofilopoulos AN: Interferons as pathogenic effectors in autoimmunity. Immunol Rev. 2005, 204: 9-26. 10.1111/j.0105-2896.2005.00252.x.
Zhang XN, Liu JX, Hu YW, Chen H, Yuan ZH: Hyper-activated IRF-1 and STAT1 contribute to enhanced Interferon stimulated gene (ISG) expression by Interferon alpha and gamma co-treatment in human hepatoma cells. Biochim Biophys Acta. 2006, 1759: 417-425.
Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002, 416: 552-556. 10.1038/416552a.
Wang J, He H, Yu L, Xia HH, Lin MC, Gu Q, Li M, Zou B, An X, Jiang B, Kung HF, Wong BC: HSF1 down-regulates XAF1 through transcriptional regulation. J Biol Chem. 2006, 281: 2451-2459. 10.1074/jbc.M505890200.
Wang J, Peng Y, Sun YW, He H, Zhu S, An X, Li M, Lin MC, Zou B, Xia HH, Jiang B, Chan AO, Yuen MF, Kung HF, Wong BC: All-trans retinoic acid induces XAF1 expression through an interferon regulatory factor-1 element in colon cancer. Gastroenterology. 2006, 130: 747-758. 10.1053/j.gastro.2005.12.017.
Grander D, Einhorn S: Interferon and malignant disease--how does it work and why doesn't it always?. Acta Oncol. 1998, 37: 331-338. 10.1080/028418698430548.
Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA, Abbruzzese A: Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol. 2005, 202: 323-335. 10.1002/jcp.20137.
Yoshida J, Mizuno M, Wakabayashi T: Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004, 95: 858-865. 10.1111/j.1349-7006.2004.tb02194.x.
Van Geelen CM, de Vries EG, de Jong S: Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat. 2004, 7: 345-358. 10.1016/j.drup.2004.11.002.
Ruiz de Almodovar C, Lopez-Rivas A, Ruiz-Ruiz C: Interferon-gamma and TRAIL in human breast tumor cells. Vitam Horm. 2004, 67: 291-318.
Yang X, Thiele CJ: Targeting the tumor necrosis factor-related apoptosis-inducing ligand path in neuroblastoma. Cancer Lett. 2003, 197: 137-143. 10.1016/S0304-3835(03)00093-4.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/7/52/prepub
We would like to thank Dr. D. McManus for providing the U6 RNA PolIII promoter and all the staff of ARC and the CHEO Research Institute for their helpful technical assistance and discussions. This work was supported by grants from the Canadian Institutes of Health Research (CIHR) and the Howard Hughes Medical Institute (HHMI). HHC is a recipient of a post-doctoral Fellowship from the CIHR. SP is a recipient of a post-doctoral Fellowship from the Natural Sciences and Engineering of Research Council of Canada (NSERC). RGK is a HHMI International Research Scholar and a Fellow of the Royal Society of Canada.
The author(s) declare that they have no competing interests.
OCM carried out the experiments and wrote the first draft. HHC did experiments and helped to draft the manuscript. SP provided technical expertise, helped to draft, and finalized the manuscript. SLH provided technical help at the DNA methylation analysis. EL aided in the generation of XAF1 shRNA vectors. PL and RGK both conceived and coordinated the study. All authors read and approved the final manuscript.